Back to search results

Virtual Reality for Psychological Symptoms in Cancer Patients

This study is testing a Virtual Reality (VR) Intervention to help cancer patients manage psychological symptoms like anxiety and depression during treatment. The VR Intervention involves a single 20-30 minute session where you'll experience calming virtual environments, such as nature scenes or guided meditations. Researchers want to see if this VR experience is easy to use and helpful for patients. You might be able to join if you are 18-90 years old, have a history of cancer, and are currently receiving inpatient chemotherapy, bone marrow transplant (BMT), CAR-T therapy, or outpatient chemotherapy. The study aims to enroll 24 participants.

Study design
This is an interventional study with a planned enrollment of 24 participants. It is not specified if it is randomized or blinded.
What's involved
You would complete questionnaires before and after a single 20-30 minute Virtual Reality (VR) Intervention session.
Compensation
Not stated in the trial record.
Follow-up
Feasibility and acceptability are measured at baseline, which is when the VR intervention is successfully completed and administered.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07221409

Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment

Recruiting
NAAges 18–90InterventionalSupportive care
Mayo Clinic
~24 participants
Updated 2026-04-02 on ClinicalTrials.gov
What's tested:Questionnaire AdministrationVirtual Reality (VR) Intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Successfully complete the virtual reality (VR) intervention (Feasibility)
Measured over Baseline
+2 more outcomes measured

Conditions

Adjustment Disorder
Anxiety Disorder
Depression
Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm
Cancer

Explore related trials

Hematopoietic and Lymphatic System NeoplasmMalignant NeoplasmMalignant Solid Neoplasm

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Juan C. Cardenas Rosales, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Wendi Lehman
[email protected]
904-953-8742
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

History of cancer
Age between 18 to 90 years
Undergoing in-patient chemotherapy, bone marrow transplant (BMT), chimeric antigen receptor (CAR)-t, \& out-patient chemotherapy

Exclusion

History of bipolar disorder, major depression, bipolar disorder, anxiety disorder, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), psychotic disorder, schizophrenia, personality disorder, substance use disorder other than caffeine or tobacco. History of suicidal ideation or attempt
History of treatment resistant depression, psychiatric hospitalization, syncope, transient ischemic attack (TIA), stroke, epilepsy, electroconvulsive therapy, benign positional vertigo, Meniere's disease

What this trial measures

  • Successfully complete the virtual reality (VR) intervention (Feasibility)Baseline

    Feasibility of VR will be assessed by the proportion of participants who successfully complete the intervention.

  • Absence of major issues during administration (Feasibility)Baseline

    Feasibility of VR will be evaluated by the absence of (low/no recorded incidence of) major technical or usability issues during administration

  • AcceptabilityBaseline

    Will be assessed via the Post-Study Exit Interview Questionnaire, a questionnaire developed specifically for this study. It consists of 17 questions. Eight questions relate to the VR experience (e.g., comfort of headset, control of actions in VR environment, understandability of instructions, technical issues). Five questions relate to symptoms (e.g., dizziness, nausea, headache) or discomfort experienced during and immediately following VR use. The remaining questions relate to helpfulness of intervention, improvement suggestions, other feedback, and interest in learning more about services and resources. Results will be analyzed descriptively.